VivoSim Labs, Inc. Restructuring and Related Cost, Number of Positions Eliminated
VivoSim Labs, Inc. (VIVS) had Restructuring and Related Cost, Number of Positions Eliminated of 6 Employees as of 2023-08-18, per its 10-K filed 2025-06-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated · last filed 2025-06-05
- VivoSim Labs, Inc. restructuring and related cost, number of positions eliminated for the quarter ending 2019-09-30 was 46.00 Employee.
- VivoSim Labs, Inc. restructuring and related cost, number of positions eliminated for fiscal 2020 was 52.00 Employee.
Employee
| Period end | Restructuring and Related Cost, Number of Positions Eliminated 3 month | Restructuring and Related Cost, Number of Positions Eliminated 9 month | Restructuring and Related Cost, Number of Positions Eliminated 12 month |
|---|---|---|---|
| 2020-03-31 | 52.00 Employee 10-K · filed 2021-06-15 | ||
| 2019-12-31 | 52.00 Employee 10-Q · filed 2020-02-10 | ||
| 2019-09-30 | 46.00 Employee 10-Q · filed 2019-11-07 |
Employees
| Period end | Restructuring and Related Cost, Number of Positions Eliminated |
|---|---|
| 2023-08-18 | 6.00 Employees 10-K · filed 2025-06-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |